Our lastest news on Orsiro DES

| 15:00 PM Europe/Amsterdam

FDA Approval and First Implant of Orsiro Mission Drug-Eluting Stent System in the U.S.

Full Commercial Launch Underway for One of the Most Studied and Thinnest Strut Drug-Eluting Stents, Offering Enhanced Deliverability

LAKE OSWEGO, Oregon - BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES). The
| 16:00 PM Europe/Amsterdam

BIOTRONIK Awarded Group Purchasing Contract for Coronary Products from Vizient

Contract Offers Increased Savings to More than Half of Nation’s Healthcare Organizations for BIOTRONIK’s Coronary Products Including the Orsiro Drug Eluting Stent

BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven, healthcare performance improvement company in the United States. The
| 13:48 PM Europe/Amsterdam

BIOTRONIK’s Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro’s Ability to Outperform Abbott’s Xience

BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical
| 14:44 PM Europe/Amsterdam

FDA Approves BIOTRONIK’s Ultrathin Orsiro Stent for the Treatment of Coronary Artery Disease

Orsiro Achieves Statistically Lower Clinical Event Rates and Superior Patient Outcomes

BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience. Orsiro received CE
| 19:25 PM Europe/Amsterdam

TCT Congress 2018: BIOTRONIK’s Orsiro Ultrathin Drug-Eluting Stent Further Outperforms Xience at Two-Year Follow-Up

Randomized Controlled Trial Data Presented at TCT Continues to Show Significantly Lower Event Rates with Orsiro in the BIOFLOW-V Trial

Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro and Xience drug-eluting stents (DES). The data shows statistically improved outcomes for patients